-

KCAS Bioanalytical and Biomarker Services Welcomes Senior Director of Biopharmaceutical Services

KANSAS CITY, Kan.--(BUSINESS WIRE)--KCAS Bioanalytical and Biomarker Services, a laboratory services focused contract research organization (CRO) is pleased to announce the addition of. Dr. Cheikh Kane, Ph.D., as a Senior Director of Biopharmaceutical Services to expand and strengthen our offering and technical expertise.

Dr. Kane, a well-recognized bioanalytical leader, brings extensive experience of implementing strategic initiatives and technical expansion within organizations spanning from Pharma to CRO businesses. Dr. Kane will bring unique circular industry experience from Biotech to Pharma and from small CROs to big CROs.

“I am thrilled about joining KCAS and working with this seasoned executive team to define and implement strategic and technical initiatives to expand KCAS' footprint in the bioanalytical field. My role will be to serve as a scientific and technical lead for both clients and internal teams with the corporate goal of strategic and organic growth of both the scientific staff and KCAS’ scientific offerings,” stated Dr. Kane.

“We are excited to have Dr. Kane join our team and lead our technical development service in biopharmaceuticals. His credentials and expertise in this sector have become well known and now position KCAS to evolve our ability to be the go-to outsourcing provider for the industry’s bioanalytical drug development needs," stated John Bucksath, CEO.

Dr. Kane joins KCAS from Nexelis (Formerly Pacific Biomarkers) based in Seattle, Washington, where he was the Senior Director of Bioanalytical and Biomarker Services. Previously he worked at Boehringer Ingelheim US, based in Ridgefield, Connecticut, where he held the position of Principal Scientist/ADA-Immunogenicity group leader. Dr. Kane earned his Ph.D. in Virology (Microbiology)-Immunology from the INRS-Institut Armand Frappier in Canada.

About KCAS

KCAS Bioanalytical and Biomarker Services, an Integris BioServices, LLC Company, is a rapidly growing company that provides comprehensive GLP / GCP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS’ headquarters is located in Shawnee, Kansas – within the Kansas City metro area – and the company employs more than 180 employees. Visit www.kcasbio.com for more information about the Company.

Contacts

KCAS Bioanalytical and Biomarker Services
Jeremy Burt
Jeremy.burt@kcasbio.com
(913) 248-3000

KCAS Bioanalytical and Biomarker Services

Details
Headquarters: Olathe, Kansas
CEO: John Bucksath
Employees: 380
Organization: PRI

Release Versions

Contacts

KCAS Bioanalytical and Biomarker Services
Jeremy Burt
Jeremy.burt@kcasbio.com
(913) 248-3000

More News From KCAS Bioanalytical and Biomarker Services

The KCAS Bio – Lyon, France Site Renews Its GLP Compliance Statement, Strengthening Its Support for IND-Enabling Studies Through Bioanalysis and Biomarkers

KANSAS CITY, Kan.--(BUSINESS WIRE)--KCAS Bio today announced that its European site in Lyon, France, has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP) according to Directive 2004/9/CE (safety tests), confirming the site’s continued ability to deliver GLP-grade bioanalytical methods in support of preclinical studies. The GLP test facility once again earned a Level of Compliance “A,” reinforcing KCAS Bio’s capability to support critical investigational new...

KCAS Bio Strengthens Board of Directors with Appointment of Paul Kirchgraber and Kurt Doyle

OLATHE, Kan.--(BUSINESS WIRE)--KCAS Bio, a leading contract research organization (CRO) specializing in comprehensive bioanalytical and biomarker services, is delighted to announce the appointment of Dr. Paul Kirchgraber and Mr. Kurt Doyle to its Board of Directors. Their addition marks a significant milestone in KCAS Bio’s continued growth and strategic evolution in the global life sciences industry. KCAS Bio is headquartered in the Kansas City, Kansas metropolitan area with operating sites in...

KCAS Bio and Crux Biolabs Announce Global Spectral Flow Cytometry Alliance

KANSAS CITY, Kan.--(BUSINESS WIRE)--KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a leading provider of flow cytometry and bioanalytical services located in Melbourne, Australia. KCAS Bio is a leading international Contract Research Organization (CRO) providing comprehensive GLP-compliant bioanalytical and biomarker development testing services for the biotech, pharmaceutical, and cell/gene...
Back to Newsroom